-
Signature
-
/s/ Nisha Antony, as Attorney-in-Fact
-
Issuer symbol
-
CRWV
-
Transactions as of
-
25 Nov 2025
-
Net transactions value
-
-$255,768
-
Form type
-
4
-
Filing time
-
28 Nov 2025, 19:16:01 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Agrawal Nitin |
Chief Financial Officer |
C/O COREWEAVE, INC., 290 WEST MT. PLEASANT AVENUE, SUITE 4100, LIVINGSTON |
/s/ Nisha Antony, as Attorney-in-Fact |
28 Nov 2025 |
0002058038 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
CRWV |
Class A Common Stock |
Sale |
$19,319 |
-290 |
-0.19% |
$66.62 |
150,869 |
25 Nov 2025 |
Direct |
F1, F2 |
| transaction |
CRWV |
Class A Common Stock |
Sale |
$20,253 |
-300 |
-0.2% |
$67.51 |
150,569 |
25 Nov 2025 |
Direct |
F1, F3 |
| transaction |
CRWV |
Class A Common Stock |
Sale |
$20,624 |
-300 |
-0.2% |
$68.75 |
150,269 |
25 Nov 2025 |
Direct |
F1, F4 |
| transaction |
CRWV |
Class A Common Stock |
Sale |
$63,390 |
-900 |
-0.6% |
$70.43 |
149,369 |
25 Nov 2025 |
Direct |
F1, F5 |
| transaction |
CRWV |
Class A Common Stock |
Sale |
$117,775 |
-1,650 |
-1.1% |
$71.38 |
147,719 |
25 Nov 2025 |
Direct |
F1, F6 |
| transaction |
CRWV |
Class A Common Stock |
Sale |
$14,407 |
-200 |
-0.14% |
$72.04 |
147,519 |
25 Nov 2025 |
Direct |
F1, F7 |
| holding |
CRWV |
Class A Common Stock |
|
|
|
|
|
115,905 |
25 Nov 2025 |
By Spouse |
F8 |
| holding |
CRWV |
Class A Common Stock |
|
|
|
|
|
57,952 |
25 Nov 2025 |
By Yosemite 2025 GRAT |
F9 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: